Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons N, Galleron N, Huang X, Gencer S, Coen M, Tranah TH, Wendon JA, Bruce KD, Le Chatelier E, Ehrlich SD, Edwards LA, Shoaie S, Shawcross DL

Journal of Hepatology - (-) - [2021-09-00; online 2021-09-00]

Saeed Shoaie

DOI 10.1016/j.jhep.2021.09.010

Crossref 10.1016/j.jhep.2021.09.010

Publications 7.1.2